WO1999058678A3 - Antibodies to dendritic cells and human dendritic cell populations and uses thereof - Google Patents

Antibodies to dendritic cells and human dendritic cell populations and uses thereof Download PDF

Info

Publication number
WO1999058678A3
WO1999058678A3 PCT/EP1999/003218 EP9903218W WO9958678A3 WO 1999058678 A3 WO1999058678 A3 WO 1999058678A3 EP 9903218 W EP9903218 W EP 9903218W WO 9958678 A3 WO9958678 A3 WO 9958678A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
well
dcs
polypeptides
polynucleotides
Prior art date
Application number
PCT/EP1999/003218
Other languages
French (fr)
Other versions
WO1999058678A2 (en
WO1999058678A9 (en
Inventor
Ernst Peter Rieber
Original Assignee
Micromet Gmbh
Ernst Peter Rieber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Gmbh, Ernst Peter Rieber filed Critical Micromet Gmbh
Priority to DE69934792T priority Critical patent/DE69934792D1/en
Priority to AU40399/99A priority patent/AU4039999A/en
Priority to EP99923574A priority patent/EP1078060B1/en
Priority to JP2000548469A priority patent/JP2002514420A/en
Priority to IL13943599A priority patent/IL139435A0/en
Priority to CA002328415A priority patent/CA2328415A1/en
Publication of WO1999058678A2 publication Critical patent/WO1999058678A2/en
Publication of WO1999058678A3 publication Critical patent/WO1999058678A3/en
Publication of WO1999058678A9 publication Critical patent/WO1999058678A9/en
Priority to US11/524,875 priority patent/US20070014798A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Abstract

Antibodies specifically recognizing a distinct population of human dendritic cells (DCs) and methods of isolating said DCs using said antibodies. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies. Also vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. Additionally, polypeptides comprising a domain of the binding site of the aforementioned antibodies, or an antigen or epitope described above and at least one further, preferably functional domain as well as polynucleotides encoding such polypeptides. Furthermore, vectors comprising said polynucleotides, host cells transfected with said polynucleotide or vector and their use for the preparation of the above-described polypeptides. Further a method for isolating or identifying DCs as defined above as well as DCs obtainable by said method and/or characterized by recognition of the above-described antibody, and/or containing the aforementioned antigen or epitope. Moreover, a method for preparing or identifying T cells in a certain status as well as methods for identifying compounds which interfere with T cell mediated activation of immune responses. In addition kits, and compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polypeptides, polynucleotides, vectors, dendritic cells or T cells or compounds obtainable by the aforementioned method.
PCT/EP1999/003218 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof WO1999058678A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69934792T DE69934792D1 (en) 1998-05-11 1999-05-11 ANTIBODIES TO DENDRITIC CELLS AND HUMAN DENDRITIC CELL POPULATIONS AND THEIR USES
AU40399/99A AU4039999A (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
EP99923574A EP1078060B1 (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
JP2000548469A JP2002514420A (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
IL13943599A IL139435A0 (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
CA002328415A CA2328415A1 (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
US11/524,875 US20070014798A1 (en) 1998-05-11 2006-09-22 Antibodies to dendritc cells and human dendritic cell populations and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98108534.3 1998-05-11
EP98108534 1998-05-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/524,875 Division US20070014798A1 (en) 1998-05-11 2006-09-22 Antibodies to dendritc cells and human dendritic cell populations and uses thereof

Publications (3)

Publication Number Publication Date
WO1999058678A2 WO1999058678A2 (en) 1999-11-18
WO1999058678A3 true WO1999058678A3 (en) 2000-02-10
WO1999058678A9 WO1999058678A9 (en) 2001-03-22

Family

ID=8231912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003218 WO1999058678A2 (en) 1998-05-11 1999-05-11 Antibodies to dendritic cells and human dendritic cell populations and uses thereof

Country Status (8)

Country Link
US (1) US20070014798A1 (en)
EP (1) EP1078060B1 (en)
JP (2) JP2002514420A (en)
AU (1) AU4039999A (en)
CA (1) CA2328415A1 (en)
DE (1) DE69934792D1 (en)
IL (1) IL139435A0 (en)
WO (1) WO1999058678A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
CN1452636B (en) 2000-05-08 2011-06-15 塞尔德克斯医疗公司 Human monoclonal antibodies to dendritis cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
EP1594533B1 (en) 2003-01-31 2012-04-11 Celldex Research Corporation Antibody vaccine conjugates and uses therefor
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
JPWO2008056734A1 (en) * 2006-11-08 2010-02-25 国立大学法人 熊本大学 Method for producing dendritic cells from human embryonic stem cells
JP5701606B2 (en) 2007-11-07 2015-04-15 セルデックス セラピューティクス インコーポレイテッド Antibodies that bind to human dendritic cells and epithelial cells 205 (DEC-205)
US7960145B2 (en) * 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
DE102010039019B4 (en) 2010-08-06 2014-08-07 Technische Universität Dresden Antibodies against 6-sulfo LacNAc positive human dendritic cells and their use
WO2013057290A1 (en) 2011-10-21 2013-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
FR3018819A1 (en) * 2014-03-19 2015-09-25 Univ Bourgogne TREATMENT OF THE INFLAMMATORY AND DYSIMMUNITARY RESPONSE
GB201515934D0 (en) * 2015-09-09 2015-10-21 Rolls Royce Plc Method of manufacturing a gas turbine engine
KR101898032B1 (en) * 2018-04-20 2018-09-12 (주)해양정보기술 Collecting system for geodetic survey data by measuring of topography change
US20210261669A1 (en) * 2018-06-20 2021-08-26 Chugai Seiyaku Kabushiki Kaisha Method for activating immune response of target cell and composition therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404097A2 (en) * 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
WO1993004187A1 (en) * 1991-08-14 1993-03-04 Medical Research Council Monoclonal antibody specific for an antigen on dendritic cells
WO1995012409A1 (en) * 1993-11-04 1995-05-11 Canterbury Health Limited Dendritic cell-specific antibodies and methods for their preparation
WO1997004802A1 (en) * 1995-07-31 1997-02-13 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1998015579A1 (en) * 1996-10-09 1998-04-16 Canterbury Health Limited Dendritic cell-specific antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404097A2 (en) * 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
WO1993004187A1 (en) * 1991-08-14 1993-03-04 Medical Research Council Monoclonal antibody specific for an antigen on dendritic cells
WO1995012409A1 (en) * 1993-11-04 1995-05-11 Canterbury Health Limited Dendritic cell-specific antibodies and methods for their preparation
WO1997004802A1 (en) * 1995-07-31 1997-02-13 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1998015579A1 (en) * 1996-10-09 1998-04-16 Canterbury Health Limited Dendritic cell-specific antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HSU F J ET AL: "Antigen-pulsed dendritic cells are effective in inducing immune responses in patients with B-cell lymphoma (Meeting abstract).", BLOOD, (1994). VOL. 84, NO. 10, SUPPL. 1, PP. 520A. ISSN: 0903-1936., Div. Of Oncology, Stanford Univ. Medical Center, Stanford, CA., XP000857234 *
SCHAKEL K ET AL: "A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb ( M - DC8 ) and in vitro priming of cytotoxic T lymphocytes.", EUROPEAN JOURNAL OF IMMUNOLOGY, (1998 DEC) 28 (12) 4084-93., XP000857207 *
SNAPP, KAREN R. ET AL: "A novel P- selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L- selectin", BLOOD (1998), 91(1), 154-164, XP002123922 *

Also Published As

Publication number Publication date
DE69934792D1 (en) 2007-02-22
WO1999058678A2 (en) 1999-11-18
JP2002514420A (en) 2002-05-21
US20070014798A1 (en) 2007-01-18
CA2328415A1 (en) 1999-11-18
JP2007125012A (en) 2007-05-24
EP1078060B1 (en) 2007-01-10
IL139435A0 (en) 2001-11-25
WO1999058678A9 (en) 2001-03-22
EP1078060A2 (en) 2001-02-28
AU4039999A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
WO1999058678A3 (en) Antibodies to dendritic cells and human dendritic cell populations and uses thereof
IE811595L (en) Synthetic peptide antigens
CA2110518A1 (en) Ctla4 receptor, fusion proteins containing it and uses thereof
WO1995029193A3 (en) Melanoma antigens
CA2348379A1 (en) Immunoassay for measuring human c-peptide and kit therefor
EP1348715A3 (en) CD19xCD3 specific polypeptides and uses thereof
WO2000067761A8 (en) Compositions and methods for identifying antigens which elicit an immune response
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
KR910002468A (en) Antibodies to Human Interleukin-6 Receptor
CA2025597A1 (en) Vaccine against lyme disease
EA200600390A1 (en) CHEMICAL ANTIGENS FOR DISTURBANCE OF THE TOLERANCE OF THE OWNER TO THE ALIEN ANTIGENS
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
WO2001079274A3 (en) Tuberculosis antigens and methods of use thereof
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
WO2001090151A3 (en) Human receptor proteins; related reagents and methods
WO2004093808A3 (en) Novel tumor-associated antigens
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2002035237A3 (en) Method for in vivo identification of intracellular epitopes
WO2000063385A3 (en) Nucleic acid immunization
WO2005092922A3 (en) Antigen of the pm-2 antibody and use thereof
AP2368A (en) Novel expression vectors and uses thereof.
ES8700056A1 (en) Glycosidic linkage related antigen, process for producing the same and anticancer agent containing the same as effective component.
WO2002094313A3 (en) Vaccine composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 139435

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 40399/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2328415

Country of ref document: CA

Ref country code: CA

Ref document number: 2328415

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999923574

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09700200

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999923574

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 12 AND 13, DESCRIPTION, REPLACED BY NEW PAGES 12 AND 13; PAGE 79, CLAIMS, REPLACED BY A NEW PAGE 79; PAGES 76 AND 77, FORM PCT/RO/134, INDICATIONS RELATING TO DEPOSITED MICROORGANISM, REPLACED BY NEW PAGES 76 AND 77; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999923574

Country of ref document: EP